Guide provided by ASNC for application of F-18 MPI radiotracers
The American Society of Nuclear Cardiology (ASNC) has recently published a new information statement in the Journal of Nuclear Cardiology. The statement, intended for the entire nuclear cardiology team, sets the stage for additional F-18 perfusion tracers currently in development.
The new guidance provides instructions for the safe and effective use of F-18 myocardial perfusion imaging (MPI) radiopharmaceuticals. This is a significant development, as these new radioisotopes, such as F-18 flurpiridaz (Flyrcado, GE HealthCare), differ significantly from the tracers that have been previously used, like rubidium-82 and nitrogen-13 ammonia.
The new information statement was authored by the German Interdisciplinary Association of Critical Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin, DIVI). It includes radiation, clinical, protocol, and interpretation information, making it a comprehensive guide for the nuclear cardiology team.
The launch of F-18 flurpiridaz marks the first PET MPI tracer approved in the U.S. in 30 years. This new guidance is expected to facilitate its safe and effective application, contributing to improved diagnostic accuracy in nuclear cardiology.
The ASNC has emphasised that this new information statement is intended for the nuclear cardiology team. The publication of this statement in the Journal of Nuclear Cardiology underscores its importance and relevance to the field.
Read also:
- Nightly sweat episodes linked to GERD: Crucial insights explained
- Antitussives: List of Examples, Functions, Adverse Reactions, and Additional Details
- Asthma Diagnosis: Exploring FeNO Tests and Related Treatments
- Unfortunate Financial Disarray for a Family from California After an Expensive Emergency Room Visit with Their Burned Infant
